MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.4 USD | +2.20% |
|
+0.90% | +19.59% |
| May. 02 | Merck: encouraging results in gastric cancer | CF |
| May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
ETFs positioned on Merck & Co., Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 0 M€ | +10.86% | - | |
| 5.61% | 0 M€ | +5.64% | - | |
| 2.85% | 9 M€ | -.--% | - | |
| 2.80% | 2 M€ | -.--% | - | |
| 2.63% | 5 M€ | -72.95% | - | |
| 2.08% | 0 M€ | -.--% | ||
| 1.96% | 16 M€ | -3.37% | ||
| 1.96% | 13 M€ | -.--% | - | |
| 1.96% | 3 M€ | +7.32% | - | |
| 1.96% | 1 M€ | +11.94% | - | |
| 1.95% | 0 M€ | +8.27% | ||
| 1.91% | 0 M€ | +13.34% | - | |
| 1.84% | 0 M€ | +3.14% | ||
| 1.50% | 9 M€ | -4.31% | - | |
| 1.43% | 0 M€ | +6.93% | ||
| 1.40% | 0 M€ | +6.67% | ||
| 1.35% | 2 M€ | +14.69% | - | |
| 1.17% | 3 M€ | +15.16% | - | |
| 1.17% | 4 M€ | -.--% | - | |
| 1.17% | 13 M€ | -.--% | - | |
| 1.13% | 92 M€ | +0.06% | - | |
| 1.08% | 0 M€ | +7.87% | ||
| 1.05% | 36 M€ | +22.19% |
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
130.4
USD
Average target price
141.6
USD
Spread / Average Target
+8.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.59% | 323B | |
| +33.43% | 690B | |
| +26.43% | 546B | |
| -5.12% | 358B | |
| +4.89% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.26% | 161B | |
| -3.54% | 159B |
- Stock Market
- Equities
- MRK Stock
- Funds and ETFs Merck & Co., Inc.